All In Biotech

Drug Trial Radar · NCT07169175

A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS

A Multicenter, Open-label, Single-arm, Dose Escalation and Expansion, Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SNUG01 in Adult Subjects With Amyotrophic Lateral Sclerosis (ALS)

Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

21

Planned (sponsor's estimate)

Start

Dec 1, 2025

Primary completion

Mar 30, 2028

Study completion Sep 30, 2028

Sponsor

Sponsor type
Industry
First posted
Sep 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy of SNUG01 in in adult subjects with Amyotrophic Lateral Sclerosis (ALS).

Conditions

  • Amyotrophic Lateral Sclerosis (ALS)

Interventions

  • SNUG01Drug

    AAV (adeno-associated virus) Gene therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The safety and tolerability of SNUG01 administered by intrathecal.Time frame: up to 1 year after administration
  2. To recommend the optimal expansion dose of SNUG01 that demonstrates acceptable safety with maximum preliminary efficacy administered by IT.Time frame: up to 1 years

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China

  • Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.